Fig. 6.

Therapeutic efficiency of punicalagin against cervical tumors. BALB/c-nu/nu mice with the HeLa cell xenograft tumor of diameter 5 mm were injected with punicalagin (20 mg/kg bodyweight) or phosphate-buffered saline (PBS) (control) once every two days. (A) Tumor diameter was measured once every two days for 18 days. (B) Tumor weight in the two groups was measured (upper panel) and representative images of the tumors were captured on day 18 when all mice were sacrificed (low panel). (C) The E6, E7, LC3-II, and cleaved CASP3 levels in the tumor tissues were examined using western blotting. (D) Representative images of tumor sections stained with hematoxylin and eosin and tumor infiltration of inflammatory cells were indicated by black arrows and immunohistochemical analysis of E6 and E7. * p<0.05. Data are expressed as mean ± standard deviation (6 mice/group). The experiments were performed twice with similar results.